Our paper in @nature.com is finally published: a prospective trial of a personalized Neoantigen Vaccine in Kidney Cancer

www.nature.com/articles/s41...

This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab

www.nature.com/articles/s41...

Another argument against removing “cancer” label for Pattern 3 easily prostate cancer refuted by replacing “pattern 3” with “benign”: men with pattern 3 / biopsy and PSA > 20 are at increased risk of mortality therefore call pattern 3 / benign “cancer” euoncology.europeanurology.com/article/S258...

Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm
acsjournals.onlinelibrary.wiley.com/doi/epdf/10....

Patient-centered pathology reports improved patients' understanding of prostate biopsy results and their ability to accurately assess their cancer diagnosis and risk level, compared to standard pathology reports.

ja.ma/4a3c38z

Estimated 6 Million deaths from breast, cervical, colorectal, lung, and prostate cancers were averted in the US from 1975 to 2020 due to Prevention, Screening, and Treatment Advances @jama.com

jamanetwork.com/journals/jam...

Just out in @bmj.com, our "Uncertainties in Practice" article on #LATP vs #TRUS

We highlight evidence so far, discordance between recommendations (@UroWeb.bsky.social vs @NIHR.bsky.social vs #AUA) & need for nuance (!)

Not long now until #TranslateTrial...

bmj.com/content/387/bm…👈

While I totally agree on the need for BCR risk stratification, i do not know if PSADT will remain that important in the new era of PSMA imaging and MDT. EMBARK isnt a risk stratification, this cohort was choosen because no one doubts they need therapy immediately.

ascopubs.org/doi/10.1200/...

💥 Just published💥
Wondering how #PSMA imaging and #genetics will influence focal therapy for #prostatecancer in the future? This book chapter discusses how modern patient selection for #focal therapy can improve cancer control outcomes.

Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR!

www.nature.com/articles/s41...

Maybe it is because in PEACE-1, pts on ADT alone had abi at PSA progression, and RT delayed PSA progression. Any benefit from RT could have been lost by harm from delayed abi

PEACE-1 trial of prostate radiotherapy in mHSPC. Improvement in rPFS when used in addition to ADT and abiraterone. Medsky. Oncsky.

Industry Announcement: CAPItello281 Phase III Source AstraZeneca

Capivasertib combined with/ADT improved rPFS in PTEN-deficient met hormone-sensitive #ProstateCancer Vs abiraterone & ADT w/placebo
OS data immature, early indications suggest potential OS benefit

www.astrazeneca.com/media-centre...

🚨🚨Prostate and UREthra on MRI (PURE-MRI):
Try to contour (outline) the prostate and urethra on MRI for 1 patient
After everyone is done, we will enable the “answer key”
And you help us learn how to help doctors and AI do better
Sign up here: redcap.link/PURE-MRI
🙏🏼

Mechanisms of resistance to PARP inhibitors in advanced prostate cancer with BRCA2/PALB2 alterations: Reversion mutations emerge within 16 weeks. These associate with disease progression and survival.
#Cancer #Oncology @oncoalert.bsky.social @apccc.bsky.social
www.sciencedirect.com/science/arti...

'TrialGPT' A new chatGPT for clinical trials @natureportfolio.bsky.social:

- 3 steps: TrialGPT-Retrieval, TrialGPT-Matching, TrialGPT-Ranking
- Retrieval identified 90% suitable trials
- 42% time-saving in matching a patient to a trial

Like, wow
#MedSky #OncSky #LCSM
www.nature.com/articles/s41...

What’s your single favorite #prostatecancer paper of the year so far?

I’ll lead with PI-CAI: big leap forward for prostate MRI through a highly collaborative AI effort. And the best part is it’s all free and *open-source*! ⭐️

www.thelancet.com/journals/lan...